Guidelines for the Safe Administration of High-Dose Interleukin-2

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 287-293

  Schwartzentruber, Douglas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

High dose IL 2; Melanoma; Renal cell carcinoma; Toxicity

Indexed keywords

ALUMINUM HYDROXIDE; ATROPINE; BICARBONATE; CEFAZOLIN; CLINDAMYCIN; CODEINE SULFATE; DIPHENOXYLATE; DOPAMINE; DROPERIDOL; GLUCONATE CALCIUM; GRANISETRON; HALOPERIDOL; INDOMETACIN; INTERLEUKIN 2; LOPERAMIDE; LORAZEPAM; MAGNESIUM HYDROXIDE; MAGNESIUM SULFATE; ONDANSETRON; PARACETAMOL; PETHIDINE; PHENYLEPHRINE; POTASSIUM CHLORIDE; POTASSIUM DIHYDROGEN PHOSPHATE; PROCHLORPERAZINE; RANITIDINE; SIMETHICONE; SODIUM CHLORIDE; TEMAZEPAM; UNINDEXED DRUG; ZOLPIDEM;

ANEMIA; BLOOD TRANSFUSION; CANCER REGRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DOSE CALCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG APPROVAL; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHYROIDISM; INTENSIVE CARE; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NAUSEA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAFETY; SIDE EFFECT; TREATMENT OUTCOME;

CAPILLARY LEAK SYNDROME; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FLUID THERAPY; HUMANS; HYPOTENSION; INTERLEUKIN-2; MELANOMA; PLEURAL EFFUSION;

EID: 0034852781     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00004     Document Type: Review

References (15)

1. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228: 307-19.
2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1): S55-7.
3. Atkins MB, Kunkel L. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 (Suppl 1): S11-4.
4. Schwartzentruber DJ. Interleukin-2: clinical applications. Principles of administration and management of side effects. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000, 32-50.
5. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998; 83: 797-805.
6. Pockaj BA, Yang JC, Lotze MT, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother 1994; 15: 22-8.
7. Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J Clin Oncol 1994; 12: 2714-22.
8. Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother 1994; 16: 60-5.
9. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993; 11: 136-47.
10. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107: 293-300.
11. MacFarlane MP, White Jr, RL, Seipp CA, Einhorn JH, White DE, Rosenberg SA. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995; 75: 1030-7.
12. Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989; 7: 1852-62.
13. White Jr, RL, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74: 3212-22.
14. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother 1996; 18: 272-8.
15. Mavroukakis SA, Muehlbauer PM, White RL, Jr, Schwartzentruber DJ. Clinical pathways for managing patients receiving interleukin 2. J Clin Oncol Nursing (in press).